Drug evaluation: Tesamorelin, a synthetic human growth hormone releasing factor

Current Opinion in Investigational Drugs

Volumn 7, Issue 10, 2006, Pages 936-945

  Tomlinson, Brian ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE; GROWTH HORMONE RELEASING FACTOR; GROWTH HORMONE SECRETAGOGUE; HEXARELIN; HUMAN GROWTH HORMONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MF 6003; PLACEBO; SERMORELIN; SOMATOMEDIN C; TESAMORELIN; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; ARTHRALGIA; BONE INJURY; CARPAL TUNNEL SYNDROME; CLINICAL TRIAL; COGNITIVE DEFECT; CONTROLLED RELEASE FORMULATION; DIARRHEA; DRUG ABSORPTION; DRUG DESIGN; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG INDUSTRY; DRUG METABOLISM; DRUG POTENCY; DRUG SCREENING; DRUG SYNTHESIS; EMBRYOTOXICITY; FETOTOXICITY; FLUID RETENTION; GROWTH HORMONE DEFICIENCY; HIP FRACTURE; HORMONE INHIBITION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HYPERGLYCEMIA; IMMUNE RESPONSE; IMMUNOPATHOLOGY; INFERTILITY; INFLUENZA; INJECTION SITE IRRITATION; INJECTION SITE REACTION; INSOMNIA; INSULIN RESISTANCE; LIPODYSTROPHY; LIVER DYSFUNCTION; METABOLIC SYNDROME X; MUSCLE ATROPHY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PAIN; PARESTHESIA; PATENT; REVIEW; SIDE EFFECT; SLEEP DISORDER; STRUCTURE ACTIVITY RELATION; TRANSDERMAL PATCH;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE III; COGNITION DISORDERS; DIABETES MELLITUS, TYPE 2; GROWTH HORMONE-RELEASING HORMONE; HIP FRACTURES; HIV WASTING SYNDROME; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; LIPID METABOLISM; PEPTIDES; RECOMBINANT PROTEINS; SLEEP DISORDERS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33750381449     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (69)

1. 182328 Theratechnologies Inc (company prospectus). Theratechnologies Inc COMPANY PROSPECTUS 1993 December 08
2. 195213 Semisynthesis of human growth hormone-releasing factors by α-amidating enzyme catalyzed oxidation of glycine-extended precursors. Bongers J, Felix AM, Campbell RM, Lee Y, Merkler DJ, Heimer EP PEPT RES 1992 5 4 183-189
3. 215785 Semisynthesis of human growth hormone-releasing factor by trypsin catalyzed coupling of leucine amide to a C-terminal acid precursor. Bongers J, Offord RE, Felix AM, Campbell RM, Heimer EP INT J PEPT PROTEIN RES 1992 40 3-4 268-273
4. 215789 Comparison of enzymatic semisyntheses of peptide amides: Human growth hormone releasing factor and analogs. Bongers J, Offord RE, Felix AM, Lambros T, Liu W, Ahmad M, Campbell RM, Helmer EP BIOMED BIOCHIM ACTA 1991 50 10-11 S157-S162
5. 217250 Theratechnologies Inc/partnership agreement with US company. Theratechnologies Inc PRESS RELEASE 1996 August 22
6. 238940 Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. Geref International Study Group. Thorner M, Rochiccioli P, Colle M, Lanes R, Grunt J, Galazka A, Landy H, Eengrand P, Shah S J CLIN ENDOCRINOL METAB 1996 81 3 1189-1196
7. 240227 Theratechnologies Inc unveils its development strategy for its second GRF analogue (TH 9507). Theratechnologies Inc PRESS RELEASE 1997 March 26
8. 285483 Serono launches Geref (sermorelin acetate for injection), provides new approach to treating pediatric growth hormone deficiency. Serono Laboratories Inc PRESS RELEASE 1998 April 27
9. 294303 Synthesis and biological activities of highly patent antagonists of growth hormone-releasing hormone. Zarandi M, Horvath JE, Halmos G, Pinski J, Nagy A, Groot K, Rekasi Z, Schally AV PROC NATL ACAD SCI USA 1994 91 25 12298-12302
10. 305864 The somatogenic hormones and insulin-like growth factor-1: Stimulators of lymphopoiesis and immune function. Clark R ENDOCR REV 1997 18 2 157-179
11. 311254 Theratechnologies Inc: Phase I clinical trial begins for ThGRF1-44. Theratechnologies Inc PRESS RELEASE 1999 January 11
12. 330480 Theratechnologies announces positive results of phase I clinical trial on ThGRF 1-44. Theratechnologies Inc PRESS RELEASE 1999 July 05
13. 374004 Theratechnologies raises additional $3.2 million following last public offering. Theratechnologies Inc PRESS RELEASE 2000 July 11
14. 385998 Theratechnologies files IND to begin phase II Canadian trial in sleep indication. Theratechnologies Inc PRESS RELEASE 2000 October 17
15. 2), a synthetic GH secretagogue, in humans. Broglio F, Benso A, Gottero C, Muccioli G, Deghenghi R, Ghigo E, Arvat E EUR J ENDOCRINOL 2000 143 3 419-425
16. 395620 Theratechnologies files two INDs for ThGRF1-44. Theratechnologies Inc PRESS RELEASE 2001 January 09
17. 398911 Theratechnologies initiates the first of two phase II clinical trials in sleep disorders. Theratechnologies Inc PRESS RELEASE 2001 February 13
18. 418455 Theratechnologies files to start phase II trial of ThGRF in influenza. Theratechnologies Inc PRESS RELEASE 2001 August 08
19. 422568 Hexarelin (examorelin): Overview and short profile. Mediolanum Farmaceutici SpA COMPANY WORLD WIDE WEB SITE 2001 September 20
20. 433843 Theratechnologies launches new collaboration with ALZA Corporation involving second promising peptide. Theratechnologies Inc PRESS RELEASE 2001 December 17
21. 438508 Theratechnologies and Sakai Chemical sign landmark licensing agreement to develop and market ThGRF peptide in Japan. Theratechnologies Inc PRESS RELEASE 2002 February 05
22. 453007 Theratechnologies's ThGRF increases sleep efficiency. Theratechnologies Inc PRESS RELEASE 2002 May 29
23. 453774 Theratechnologies' ThGRF improves immune function in elderly. Theratechnologies Inc PRESS RELEASE 2002 June 06
24. 490680 Theratechnologies initiates phase II clinical trial in Canada and the US for ThGRF in HIV-related lipodystrophy. Theratechnologies Inc PRESS RELEASE 2003 May 22
25. 516684 Theratechnologies' ThGRF does not improve hip fracture recovery. Theratechnologies Inc PRESS RELEASE 2003 December 09
26. 533110 Theratechnologies' ThGRF shows promise in HIV-associated lipodystrophy. Theratechnologies Inc PRESS RELEASE 2004 16 April
27. 556253 Effects of TH9507, a growth hormone releasing factor (GRF) analog, on functional performance in patients with COPD. Maltais F, O'Donnell DE, Schols AMWJ, Hernandez P, Teller JM, Lussier B, Allas S, Abribat T, Vachon L EUR RESPIR J 2004 24 48 P1603
28. 556361 Anabolic effects and safety assessments of TH9507, a growth hormone releasing factor (GRF) analog, in patients with COPD-associated wasting. Schols AMWJ, Maltais F, O'Donnell DE, Hernandez P, Tellier JM, Lussier B, Alias S, Chapdelaine A, Abribat T, Vachon L EUR RESPIR J 2004 24 48 P1888
29. 556420 Theratechnologies presents results from its HIV-associated lipodystrophy phase II study on ThGRF at the 12th International Congress of Endocrinology. Theratechnologies Inc PRESS RELEASE 2004 August 26
30. 572837 LAB International - focused. LAB International Inc COMPANY PRESENTATION 2004 May
31. 575946 Pulmonary delivery of TH9507, a growth hormone releasing factor analogue, in the dog. Jansen M, Darby I, Abribat T, Dubreuil P, Ferdinandi ES, Hardy JG INT J PHARM 2004 276 1-2 75-81
32. 575959 TH9507: Embryofetal and fertility studies of a growth hormone-releasing factor (GRF) analogue. Ferdinandi E, Washer G, Pinsonneault L, Robinson K, Abribat T TOXICOL SCI 2003 72 1 Suppl Abs 131
33. 575960 TH9507: Safety studies of a growth-hormone releasing factor (GRF) analogue. Washer GR, Ferdinandi E, Procter B, Praslicka J, Parente C, Dubreulil P TOXICOL SCI 2003 72 1 Suppl Abs 46
34. 575961 TH9507, a growth hormone-releasing factor analogue (GRF), does not impair overall glucose control and decreases non-HDL cholesterol in patients with type 2 diabetes. Abribat T, Clemmons D, Miller S, Lussier B, Teller SM, Alias S, Alexandre B, Chapdelaine A, de Villers A, Vachon L DIABETE METABOL 2003 29 2 4 Suppl Abs 129
35. 605902 Theratechnologies: Four scientific posters at the Endocrine Society Annual Meeting. Theratechnologies Inc PRESS RELEASE 2005 June 06
36. 611002 Theratechnologies starts phase III trial of HIV lipodystrophy drug. Theratechnologies Inc PRESS RELEASE 2005 July 05
37. 625406 A placebo-controlled, dose-ranging study of a growth hormone releasing factor in HIV-infected patients with abdominal fat accumulation. Falutz J, Allas S, Kotler D, Thompson M, Koutkia P, Adbu J, Trottier B, Routy JP, Cote P, Abribat T, Grinspoon S AIDS 2005 19 12 1279-1287
38. 658611 SMART: Somatotrophics, memory and aging research trial. INTERNET SITE 2006 March www.clinicaltrials.gov
39. 683865 Growth hormone releasing hormone (GHRH) and the GHRH receptor. Lin-Su K, Wajnrajch MP REV ENDOCR METAB DISORD 2002 3 4 313-323
40. 683876 Growth hormone secretion: Molecular and cellular mechanisms and in vivo approaches. Anderson LL, Jeftinija S, Scanes CG EXP BIOL MED 2004 229 4 291-302
41. 683931 Clinical pharmacology of human growth hormone and its secretagogues. Root AW, Root MJ CURR DRUG TARGETS IMMUNE ENDOCR METABOL DISORD 2002 2 1 27-52
42. 683935 Can GHRH or GH secretagogues re-initiate pituitary GH pulsatility? Chappel S CLIN ENDOCRINOL 1999 60 5 547-56
43. 683938 Continuous subcutaneous infusions of growth hormone (GH) releasing hormone 1-44 for 14 days increase GH and insulin-like growth factor-I levels in old men. Corpas E, Harman SM, Pineyro MA, Roberson R, Blackman MR J CLIN ENDOCRINOL METAB 1993 76 1 134-138
44. 683941 Repetitive growth hormone-releasing hormone administration restores the attenuated growth hormone (GH) response to GH-releasing hormone testing in normal aging. lovino M, Monteleone P, Steardo L J CLIN ENDOCRINOL METAB 1989 69 4 910-913
45. 683944 Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men. Corpas E, Harman SM, Pineyro MA, Roberson R, Blackman MR J CLIN ENDOCRINOL METAB 1992 76 2 530-535
46. 683945 Use of growth hormone and growth hormone secretagogues in aging: Help or harm. Khorram O CLIN OBSTET GYNECOL 2001 44 4 893-901
47. 683947 Justified and unjustified use of growth hormone. van der Lely AJ POSTGRAD MED J 2004 80 948 577-580
48. 2 terminus. Frohman LA, Downs TR, Wiliams TC, Heimer EP, Pan YC, Felix AM J CLIN INVEST 1986 78 4 906-913
49. 683959 Degradation of aspartic acid and asparagine residues in human growth hormone-releasing factor. Bongers J, Heimer EP, Lambros T, Pan YC, Campbell RM, Felix AM INT J PEPT PROTEIN RES 1992 39 4 364-374
50. 683962 Carpal tunnel syndrome and gynaecomastia during growth hormone treatment of elderly men with low circulating IGF-I concentrations. Cohn L, Feller AG, Draper MW, Rudman IW, Rudman D CLIN ENDOCRINOL 1993 39 4 417-425
51. 684087 Assessment of ex vivo DPP IV proteolytic cleavage of TH9507 in rat, dog and human plasma by LC/MS. High KA, Gritsas A, Tsikos T, Flarakos T, Ferdinandi ES PROC ASMS CONF MASS SPECT ALLIED TOPICS San Antonio, TX, USA 2005
52. 685553 Endocrine and metabolic effects of TH9507, a growth hormone-releasing factor (GRF) analogue, in elderly male and female subjects. Alias S, Lussier B, Chapdelaine A, Cadeau M, Abribat T, Vachon L ENDOCR SOC 2004 86 Abs 414
53. 685556 Anchoring rigid hydrophobic chains to stabilize growth hormone-releasing factor. Larocque A, Vaillancourt C, Abribat T, Chapdelaine A, Gravel D, Dubreuil P, Ibea M, Brazeau P, Ped KG PROC AM PEPT SYMP 2001 17 Abs 382
54. 685558 Anabolic effects and safety assessment of TH9507, a growth hormone-releasing factor (GRF) analogue, in patients with COPD-associated wasting. Schols AMWJ, Maltais F, O'Donnell DE, Tellier J, Lussier B, Alias S, Chapdelaine A, Vachon TA ENDOCR SOC 2004 86 Abs 421
55. 685565 Effects of TH9507, a growth hormone-releasing factor (GRF) analogue, on health-related quality of life and respiratory muscle function in patients with COPD-associated wasting. Maltais F, O'Donnell DE, Schols AMWJ, Hernandez P, Lussier B, Alias S, Deslauriers N, Abribat T, Vachon L PROC AM THORAC SOC 2005 Abs 4342
56. 685566 TH 9507, a new growth hormone-releasing factor (GRF) analogue, is a powerful insulin-like growth factor-1 (IGF-1) inducer in 50-60 year old healthy subjects: A 7-day randomized multidose study. Abribat T, Chapdelaine A, Gravel D, Brazeau P, Aumais C ENDOCR SOC 2001 83 292
57. 685570 Effects of gender on the insulin-like growth factor-1 response to repeated administration of TH9507, a long acting growth-hormone releasing factor analogue. Alexandre B, Alias S, De Villers A, Chapdelaine A, Vachon L, Lussier B, Abribat T ENDOCR SOC 2003 86 Abs 85
58. 685575 Safety assessment and metabolic effects of TH9507, a growth-hormone releasing factor analogue, in patients with type 2 diabetes mellitus. Clemmons D, Miller S, de Villers A, Chapdelaine A, Vachon L, Lussier B, Tellier J, Alias S, Alexandre B, Abribat T ENDOCR SOC 2003 85 Abs 354
59. 685883 Theratechnologies receives SPA for phase III TH-9507 lipodystrophy trial. Theratechnologies Inc PRESS RELEASE 2006 August 24
60. 688937 Growth hormone and its disorders. Ayuk J, Sheppard MC POSTGRAD MED J 2006 82 963 24-30
61. 689218 Growth hormone and connective tissue in exercise. Doessing S, Kjaer M SCAND J MED SCI SPORTS 2005 15 4 202-210
62. 689258 Effects of TH9507, a growth hormone-releasing factor (GRF) analogue, on serum lipid parameters. Mamputu JC, Allas S, Deslauriers N, Lussier B, Vachon L, Abribat T ENDOCR SOC 2005 87 Abs 461
63. 689481 The effect of growth hormone on weight gain and pulmonary function in patients with chronic obstructive lung disease. Pape GS, Friedman M, Underwood LE, Clemmons DR CHEST 1991 99 6 1495-1500
64. 689482 Low IGF-I levels in hip fracture patients. A comparison of 20 coxarthrotic and 23 hip fracture patients. Hedstrom M, Saaf M, Dalen N ACTA ORTHOP SCAND 1999 70 2 145-148
65. 689488 Growth hormone, lymphocytes and macrophages. Kelley KW BIOCHEM PHARMACOL 1989 38 5 705-713
66. 2 administration on the immune system of aging men and women. Khorram O, Yeung M, Vu L, Yen SS J CLIN ENDOCRINOL METAB 1994 82 11 3590-3596
67. 689497 Growth hormone and sex steroid administration in healthy aged women and men: A randomized controlled trial. Blackman MR, Sorkin JD, Munzer T, Bellantoni MF, Busby-Whitehead J, Stevens TE, Jayme J, O'Connor KG, Christmas C, Tobin JD, Steveart KJ et al J AM MED ASSOC 2002 288 18 2282-2292
68. 2 for stimulation of growth in children with GH deficiency. Chen RG, Shen YN, Yei J, Wang CF, Xie DH, Wang XH, Zhou JD, Chen CY, Wu YL, Gunnarsson R ACTA PAEDIATR SUPPL 1993 388 32-35
69. 2 compared with growth hormone. Neyzi O, Yordam N, Ocal G, Bundak R, Darendeliler F, Acikgoz E, Berberoglu M, Gunoz H, Saka N, Calikoglu AS ACTA PAEDIATR SUPPL 1993 388 16-21